Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.39 |
| ▸ | MMP8 | P22894 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | CD69 | Q07108 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4236278 | 0.98 | MME (0.41) | MMEHDAC9HSD11B1MMP8PKM | |
| SCHEMBL5326427 | 0.88 | MME (0.38) | MMEHDAC9MAOAMAOB | |
| SCHEMBL23857123 | 0.80 | AKR1B1 (0.42) | HSD11B1KMT2AMAOAAKR1B1 | |
| Hydrochloric Acid SCHEMBL25200678 | 0.79 | AKR1B1 (0.41) | HSD11B1KMT2AMAOAAKR1B1 | |
| Hydrochloric Acid SCHEMBL23857210 | 0.79 | AKR1B1 (0.41) | HSD11B1KMT2AMAOAAKR1B1 | |
| SCHEMBL4239525 | 0.78 | MME (0.44) | MMEHDAC9HSD11B1MMP8PKM | |
| SCHEMBL6818072 | 0.77 | USP2 (0.48) | MMEHDAC9HSD11B1MMP8PKM | |
| SCHEMBL3315498 | 0.77 | BRD4 (0.43) | KMT2A | |
| SCHEMBL261005 | 0.76 | CYP2C19 (0.50) | MMEHDAC9HSD11B1MMP8PKM | |
| SCHEMBL25787157 | 0.76 | TSHR (0.44) | MMEHDAC9HSD11B1MMP8PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093473-A1 | Spiro-benzimidazoles as inhibitors of gastric acid secretion | NYCOMED GMBH (DE) | 2009-04-09 | — | — | US | disclosed |
| EP-1899341-A1 | SPIRO-IMIDAZNAPHTHYRIDINE DERIVATIVES AS GASTRIC ACID SECRETION INHIBITORS | Nycomed GmbH (DE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1899338-A1 | SPIRO-BENZIMIDAZOLES AS INHIBITORS OF GASTRIC ACID SECRETION | Nycomed GmbH (DE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006134111-A1 | SPIRO-BENZIMIDAZOLES AS INHIBITORS OF GASTRIC ACID SECRETION | NYCOMED GMBH (DE) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006134112-A1 | SPIRO-IMIDAZNAPHTHYRIDINE DERIVATIVES AS GASTRIC ACID SECRETION INHIBITORS | NYCOMED GMBH (DE) | 2006-12-21 | — | — | WO | disclosed |
| US-4500713-A | TETRAHYDROISOQUINOLINE-3-CARBOXYLIC ACID DERIVATIVE AS ANTIHYPERTENSIVE AGENT | USV PHARMACEUTICAL CORPORATION (US) | 1985-02-19 | — | — | US | disclosed |
| EP-0104546-A2 | Therapeutic dipeptides | USV PHARMACEUTICAL CORPORATION (US) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093473-A1 | Spiro-benzimidazoles as inhibitors of gastric acid secretion | GIPR, PGC, SLC10A2 | MME 2311/4885HDAC9 462/4885HSD11B1 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.